ClinicalTrials.gg
CompletedNCT01249664MyrrorUpdated May 5, 2014Results posted

VEGF Trap-Eye in Choroidal Neovascularization Secondary to Pathologic Myopia (mCNV)

A Phase 3 interventional study of VEGF Trap-Eye (BAY86-5321) and No Drug in Myopia, Pathological, sponsored by Bayer. Completed at 20 sites in 5 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2014-05-05.

Sponsored by Bayer · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
122
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

VEGF Trap-Eye will be tested for safety and efficacy in patients with vision loss due to choroidal neovascularization secondary to pathologic myopia. This will be a placebo-controlled trial. 3 out of 4 patients will receive an injection of VEGF Trap-Eye into the affected eye (and repeated injections if required), and 1 out of 4 patients will receive a sham injection requiring no needle stick, but making the patient unaware of whether or not he received active treatment.

Outcome of the two treatment groups will be compared after 24 weeks. From week 24, sham patients may receive active treatment.

Total duration of the study will be 48 weeks.

02

Conditions studied

  • Myopia, Pathological

Keywords

  • sham-controlled
  • pathologic myopia
  • mCNV
  • choroidal neovascularization
  • intravitreal injection
  • vision loss
  • macular damage
03

In context

Myopia, Degenerative

71 studies on the registry are indexed under Myopia, Degenerative; 20 are open to participants now.

This study's enrollment of 122 is close to the median of 122 across 57 interventional studies indexed under Myopia, Degenerative.

Browse Myopia, Degenerative studies →

Lead sponsor

Bayer is the lead sponsor of 1,674 studies on the registry; 51 are open to participants now.

Of its 214 completed or terminated interventional studies of FDA-regulated products, 132 (62%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Able to read (or, if unable to read due to visual impairment, be read to verbatim by the person administering the form or a family member) and understand the informed consent form and willing to sign the informed consent form
  • Signed informed consent form. In Japan only, the informed consent form for a subject under the age of 20 years will require the co-signature of the subject's legally authorized representative.
  • Men and women ≥ 18 years of age
  • Myopia of greater than or equal to -6 D OR axial length of greater than or equal to 26.5 mm
  • Active subfoveal or juxtafoveal (within 1 to 199 μm of the center of the fovea) CNV secondary to pathologic myopia as defined by leakage on FA
  • Best-corrected visual acuity of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye at 4 meters
  • Decrease in vision in the study eye is determined by the investigator, using his/her medical judgment, to be primarily the result of the current active mCNV
  • Willing, committed, and able to return for all clinic visits and complete all study-related procedures

Exclusion criteria

Exclusion Criteria:

  • Only one functional eye
  • Ocular media of insufficient quality to obtain fundus and OCT images in the study eye
  • Greatest linear dimension (GLD) of the lesion in the study eye is greater than 12 disc areas
  • Recurrent mCNV in the study eye
  • Aphakia in the study eye
  • History or presence of CNV with an origin other than pathologic myopia in the study eye
  • Ocular inflammation or external ocular inflammation in the study eye
  • Concurrent disease in the study eye that would compromise BCVA or require medical or surgical intervention during the study period
  • Any ocular disorder in the study eye that, in the opinion of the investigator, may confound interpretation of the study results
  • Significant scarring or atrophy in the fovea that indicates substantial irreversible vision loss in the study eye
  • History of idiopathic or -associated uveitis in either eye
  • Evidence at examination of infectious blepharitis, keratitis, scleritis, or conjunctivitis in either eye or current treatment for serious systemic infection
  • Vitreomacular traction or traction retinal detachment, epiretinal membrane in either eye
  • Any iris neovascularization and/or vitreous hemorrhage in either eye
  • Uncontrolled glaucoma, or previous filtration surgery in either eye
  • Prior and concomitant treatments
  • In the study eye:

    • Any prior or concomitant treatment with another agent for mCNV
    • Any previous panretinal photocoagulation or subfoveal thermal laser therapy
    • Any prior treatment with photodynamic therapy
    • Cataract surgery within 3 months prior to Day 1
    • Yttrium-aluminum-garnet laser capsulotomy within 2 months prior to Day 1
    • Any other intraocular surgery within 3 months prior to Day 1
    • History of vitreoretinal surgery and/or scleral buckle surgery
  • Any prior treatment with anti-VEGF agents
  • Previous use of intraocular or periocular in either eye within 3 months prior to Day 1
  • Previous assignment to treatment during this study
  • Uncontrolled hypertension
  • History of cerebrovascular disease or myocardial infarction within 6 months prior to Baseline/Day 1
  • History of other disease, metabolic dysfunction, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of an investigational drug, may affect interpretation of the results of the study, or renders the subject at high risk from treatment complications
  • Women of without , women who intend to breastfeed during the study. All subjects (both men and women) of childbearing potential who are unwilling to use adequate birth control measures during the course of the study.
  • Renal failure requiring dialysis or renal transplant
  • Participation in an investigational study within 30 days prior to Screening/Visit 1 that involved treatment with any drug (excluding vitamins and minerals) or device
  • Known serious allergy to the fluorescein sodium for injection in angiography or Verteporfin
  • Inability to obtain fundus photographs or fluorescein angiograms of sufficient quality
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
122 participants (actual)

Study arms

  • Experimental
    Arm 1

    Biological: VEGF Trap-Eye (BAY86-5321)

  • Sham comparator
    Arm 2

    Procedure: No Drug

Interventions

  • 1 intravitreal injection of the experimental drug, followed by monthly re-injections if needed

  • ProcedureNo Drug

    Sham procedure NOT involving injection of any substance; patient´s eye is anesthetized and a syringe without needle gently pressed on the cornea

06

What researchers measure

Primary outcomes

  1. Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)

    Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 24

  2. Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases

    Data as observed at visit, no carrying forward from latest observation if missing data at later time points. Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.

    Time frame: Baseline, Week 24

  3. Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 24

  4. Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 24

  5. Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 48

  6. Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 48

  7. Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 48

  8. Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 24

  9. Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 24

  10. Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 24

  11. Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 48

  12. Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 48

  13. Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF

    Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

    Time frame: Baseline, Week 48

  14. Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF

    A negative number indicates improvement (reduced thickness).

    Time frame: Baseline, Week 24

  15. Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF

    A negative number indicates improvement (reduced thickness).

    Time frame: Baseline, Week 48

  16. Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF

    CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes

    Time frame: Baseline, Week 24

  17. Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF

    CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes

    Time frame: Baseline, Week 48

  18. Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF

    EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).

    Time frame: Baseline, Week 24

  19. Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF

    The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.

    Time frame: Baseline, Week 24

  20. Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks

    Time frame: Baseline, Week 24

  21. Mean Change in Area of Leakage From Baseline at Week 24 - LOCF

    A negative change from baseline indicates improvement, ie, less leakage.

    Time frame: Baseline, Week 24

07

Results

Posted Apr 1, 2014

Participant flow

The study was conducted at 20 study centers in 5 countries. Recruitment period: 17 Dec 2010 - 28 Feb 2013.

Participant flow — Overall Study
MilestoneAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Started9131
Participants received treatment9131
Fulfilled requirements of fas population9031
Completed 24 weeks treatment8325
Completed 48 weeks treatment7824
Completed8531
Not completed60
Withdrew: Withdrawal by subject50
Withdrew: Adverse event10

Outcome measures

PrimaryMean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)

Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.

Time frame:
Baseline, Week 24
Reported as:
Mean · Letters correctly read
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)
Letters correctly readAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by Early Treatment Diabetic Retinopathy Study (ETDRS) From Baseline to Week 24 - Last Observation Carried Forward (LOCF)12.1 ± 8.3-2.0 ± 9.7
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = <0.0001 (No adjustment on P value, this is for the primary efficacy analysis.) · Difference in least square means: 14.1 · 95% CI 10.8 to 17.4The difference is calculated as Eylea minus Sham. A positive value indicates Eylea showed a higher change in BCVA total score until week 24 compared to Sham.
SecondaryPercentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Gained at Least 15 Letters in BCVA as Measured by ETDRS at Week 24 Using the LOCF Approach38.99.7
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.0001 (No adjustment on P value, since this test was only conducted formally under the primary efficacy evaluation was significant.) · Cmh adjusted difference: 29.2 · 95% CI 14.4 to 44.0A two-sided Cochran-Mantel-Haenszel method at level 5% weight-adjusted by country (country designations) was used to conduct the superiority test.
SecondaryMean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases

Data as observed at visit, no carrying forward from latest observation if missing data at later time points. Defined study baseline range of ETDRS Best Corrected Visual Acuity letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning.

Time frame:
Baseline, Week 24
Reported as:
Mean · Letters correctly read
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases
Letters correctly readAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS From Baseline to Week 24 - Observed Cases12.0 ± 8.4-0.8 ± 9.3
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = <0.0001 · Difference in least square means: 13.1 · 95% CI 9.4 to 16.7
SecondaryPercentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 24 - LOCF63.312.9
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = <0.001 · Cmh adjusted difference: 50.5 · 95% CI 35.0 to 66.0
SecondaryPercentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 24 - LOCF83.319.4
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = <0.001 · Cmh adjusted difference: 64.0 · 95% CI 47.8 to 80.3
SecondaryPercentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Gained at Least 15 Letters in BCVA at Week 48 - LOCF50.029.0
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.0308 · Cmh adjusted difference: 21.0 · 95% CI 1.9 to 40.1
SecondaryPercentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Gained at Least 10 Letters in BCVA at Week 48 - LOCF68.941.9
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.0075 · Cmh adjusted difference: 27.0 · 95% CI 7.2 to 46.8
SecondaryPercentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Gained at Least 5 Letters in BCVA at Week 48 - LOCF87.845.2
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = <.0001 · Cmh adjusted difference: 42.7 · 95% CI 23.7 to 61.6
SecondaryPercentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 24 - LOCF06.5
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.1478 · Cmh adjusted difference: -6.5 · 95% CI -15.2 to 2.3
SecondaryPercentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 24 - LOCF025.8
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.0006 · Cmh adjusted difference: -25.8 · 95% CI -40.6 to -11.0
SecondaryPercentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 24 - LOCF3.335.5
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = <0.0001 · Cmh adjusted difference: -32.2 · 95% CI -48.1 to -16.3
SecondaryPercentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Lost at Least 15 Letters in BCVA at Week 48 - LOCF1.16.5
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.2446 · Cmh adjusted difference: -5.3 · 95% CI -14.4 to 3.7
SecondaryPercentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Lost at Least 10 Letters in BCVA at Week 48 - LOCF1.122.6
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.0035 · Cmh adjusted difference: -21.5 · 95% CI -35.9 to -7.0
SecondaryPercentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF

Defined study baseline range of Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score of 73 to 35 letters (ETDRS equivalent of 20/40 to 20/200) in the study eye; a higher score represents better functioning. Nominator = (Number of participants who maintained vision \* 100); Denominator = Number of participants analyzed.

Time frame:
Baseline, Week 48
Reported as:
Number · Percentage of participants
Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Lost at Least 5 Letters in BCVA at Week 48 - LOCF3.329.0
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · Cochran-Mantel-Haenszel · p = 0.0012 · Cmh adjusted difference: -25.7 · 95% CI -41.3 to -10.1
SecondaryMean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF

A negative number indicates improvement (reduced thickness).

Time frame:
Baseline, Week 24
Reported as:
Mean · microns
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF
micronsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 24 - LOCF-79.1 ± 83.7-4.2 ± 127.4
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = <0.0001 · Difference in least square means: -77.9 · 95% CI -108.9 to -46.9
SecondaryMean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF

A negative number indicates improvement (reduced thickness).

Time frame:
Baseline, Week 48
Reported as:
Mean · microns
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF
micronsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Central Retinal Thickness (CRT) as Assessed by Optical Coherence Tomography (OCT) From Baseline to Week 48 - LOCF-83.1 ± 85.5-56.7 ± 119.0
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = 0.0650 · Difference in least square means: -29.3 · 95% CI -60.4 to 1.8
SecondaryMean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF

CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes

Time frame:
Baseline, Week 24
Reported as:
Mean · Disc areas
Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF
Disc areasAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 24 - LOCF-0.2233 ± 0.31950.3007 ± 0.4383
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = <0.0001 · Difference in least square means: -0.4808 · 95% CI -0.5990 to -0.3626
SecondaryMean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF

CNV area values measured in square millimeters, each disc area is equivalent to 2.54 mm\^2 on the retina; lower values represent better outcomes

Time frame:
Baseline, Week 48
Reported as:
Mean · Disc areas
Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF
Disc areasAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Choroidal Neovascularization (CNV) Lesion Size as Assessed by Fluorescein Angiography (FA) From Baseline to Week 48 - LOCF-0.1995 ± 0.4281-0.0111 ± 0.4031
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = 0.0256 · Difference in least square means: -0.1346 · 95% CI -0.2525 to -0.0167
SecondaryMean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF

EQ-5D is a quality of life questionnaire based on a scale from -0.594 (worst) to 1.00 (best).

Time frame:
Baseline, Week 24
Reported as:
Mean · Scores on a scale
Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF
Scores on a scaleAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in European Five-dimensional Health Scale (EQ-5D) Score From Baseline to Week 24 - LOCF0.0187 ± 0.17490.0341 ± 0.1723
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = 0.8690 · Difference in least square means: -0.0045 · 95% CI -0.0579 to 0.0490
SecondaryMean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF

The NEI VFQ-25 total score ranges from 0-100 with a score of 0 being the worst outcome and 100 being the best outcome. The NEI VFQ questionnaire is organized as a collection of subscales which are all scored from 0-100. To reach the overall composite score, each sub-scale score is averaged in order to give each sub-scale equal weight.

Time frame:
Baseline, Week 24
Reported as:
Mean · Scores on a scale
Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF
Scores on a scaleAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) Total Score From Baseline to Week 24 - LOCF3.14 ± 10.21-2.58 ± 10.07
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = 0.0104 · Difference of least square means: 5.21 · 95% CI 1.25 to 9.18
SecondaryPercentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks
Time frame:
Baseline, Week 24
Reported as:
Number · Percentage of participants
Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks
Percentage of participantsAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Percentage of Participants Who Were Withdrawn From Study Drug During the First 24 Weeks6.719.4
SecondaryMean Change in Area of Leakage From Baseline at Week 24 - LOCF

A negative change from baseline indicates improvement, ie, less leakage.

Time frame:
Baseline, Week 24
Reported as:
Mean · Disc areas
Mean Change in Area of Leakage From Baseline at Week 24 - LOCF
Disc areasAflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or Sham
Mean Change in Area of Leakage From Baseline at Week 24 - LOCF-0.4743 ± 0.48390.2094 ± 0.5088
Statistical analysis
  • Aflibercept Injection First, Then Aflibercept or Sham vs Sham Treatment First, Then Aflibercept Injection or Sham · ANCOVA · p = <0.0001 · Difference in least square means: -0.6648 · 95% CI -0.8056 to -0.5239

Adverse events

Collected over From the first study drug injection until 30 days after the last study drug injection at the latest up to week 48.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aflibercept Injection (Until Week 20)—3/91 (3.3%)30/91 (33%)
Sham Treatment (Until Week 20)—0/31 (0%)8/31 (25.8%)
Aflibercept Injection (Until Week 44)—4/91 (4.4%)18/91 (19.8%)
Sham Treatment Then Aflibercept Injection (Until Week 44)—0/31 (0%)8/31 (25.8%)
Most frequent serious events
Most frequent serious events
EventAflibercept Injection (Until Week 20)Sham Treatment (Until Week 20)Aflibercept Injection (Until Week 44)Sham Treatment Then Aflibercept Injection (Until Week 44)
Macular holeEye disorders0/910/312/910/31
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders1/910/310/910/31
Choroidal neovascularisationEye disorders0/910/311/910/31
Pneumonia moraxellaInfections and infestations0/910/311/910/31
Cerebral haemorrhageNervous system disorders1/910/310/910/31
DepressionPsychiatric disorders1/910/310/910/31
Most frequent other events
Most frequent other events
EventAflibercept Injection (Until Week 20)Sham Treatment (Until Week 20)Aflibercept Injection (Until Week 44)Sham Treatment Then Aflibercept Injection (Until Week 44)
NasopharyngitisInfections and infestations9/912/319/912/31
Posterior capsule opacificationEye disorders0/910/310/913/31
Punctate keratitisEye disorders4/913/315/913/31
Conjunctival haemorrhageEye disorders7/911/317/911/31
Dry eyeEye disorders6/911/311/911/31
Eye painEye disorders6/911/312/911/31
HeadacheNervous system disorders6/911/310/910/31
Herpes zosterInfections and infestations0/912/310/910/31
NauseaGastrointestinal disorders5/910/313/910/31

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Mean58.5 ± 13.757.5 ± 12.158.2 ± 13.3
Sex: Female, Male
Sex: Female, Male(Participants)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Female652792
Male25429
Baseline Best Corrected Visual Acuity (BCVA) letter scores
Baseline Best Corrected Visual Acuity (BCVA) letter scores(Letters correctly read)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Mean56.4 ± 9.856.6 ± 8.956.5 ± 9.5
Baseline Central Retinal Thickness by Optical Coherence Tomography (OCT)
Baseline Central Retinal Thickness by Optical Coherence Tomography (OCT)(µm)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Mean349.7 ± 91.3354.2 ± 107.2350.9 ± 95.2
Baseline intraocular pressure
Baseline intraocular pressure(mm Hg)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Mean15.2 ± 2.715.8 ± 2.815.4 ± 2.7
Number of participants by category of time since mCNV diagnosis
Number of participants by category of time since mCNV diagnosis(Participants)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
>= 2 months17724
< 2 months732497
Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score
Baseline National Eye Institute 25-item Visual Function Questionnaire (NEI VFQ-25) total score(scores on a scale)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Mean70.47 ± 13.4872.73 ± 15.2971.04 ± 13.94
European questionnaire 5 dimensions (EQ-5D) total score
European questionnaire 5 dimensions (EQ-5D) total score(score on a scale)Aflibercept Injection First, Then Aflibercept or ShamSham Treatment First, Then Aflibercept Injection or ShamTotal
Mean0.88 ± 0.180.88 ± 0.150.88 ± 0.18

5 further baseline measures are reported on the registry.

08

Study locations

20 sites
  • Kowloon, Hong Kong
  • Nagoya, Aichi 466-8560, Japan
  • Nagoya, Aichi 467-8602, Japan
  • Urayasu, Chiba 279-0021, Japan
  • Matsuyama, Ehime 790-8524, Japan
  • Sendai, Miyagi 984-8560, Japan
  • Suita, Osaka 565-0871, Japan
  • Otsu, Shiga 520-2192, Japan
  • Bunkyo-ku, Tokyo 113-8519, Japan
  • Chiyoda-ku, Tokyo 101-8309, Japan
  • Shinjuku-ku, Tokyo 160-8582, Japan
  • Fukuoka, 812-8582, Japan
  • Fukushima, 960-1295, Japan
  • Kyoto, 606-8507, Japan
  • Osaka, 545-8586, Japan
  • Osaka, 558-8558, Japan
  • Seoul, 137 701, Korea, Republic of
  • Singapore, 168751, Singapore
  • Taipei, 11217, Taiwan
  • Taoyuan, 333, Taiwan
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Dec 2010, a primary completion of Feb 2013 and a completion of Aug 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2014, 1 year 2 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 26, 2010
First posted
Nov 30, 2010
Start
Dec 2010
Primary completionActual
Feb 2013
CompletionActual
Aug 2013
Results first posted
Apr 1, 2014
Last update
May 5, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 5, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01249664
Lead sponsor
Bayer
First posted
Nov 30, 2010
Start date
Dec 2010
Primary completion
Feb 2013
Completion
Aug 2013
Results posted
Apr 1, 2014
Last update
May 5, 2014

Study contacts

Bayer Study Director
study director · Bayer

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Aflibercept

Start the discussion